Study investigator David Berg explains why volume overload shouldn't decide which hospitalized patients get an SGLT2 inhibitor.
|Videos|January 11, 2016
The Aftermath of Hepatitis C Drugs on Specialty Spending
Author(s)Davy James, Managing Editor
David Lassen, chief clinical officer at Prime Therapeutics, discusses how high cost hepatitis C drugs have impacted the entire specialty landscape.
Advertisement
David Lassen, chief clinical officer at Prime Therapeutics, discusses how high cost hepatitis C drugs have impacted the entire specialty landscape.
Advertisement
Related to this article
Advertisement
Advertisement
Trending on Pharmacy Times
1
After 180 Years, Multiple Myeloma Gets a Definition of Cure
2
FDA Approves Belzutifan Plus Lenvatinib for Advanced Renal Cell Carcinoma After Immunotherapy
3
Alcohol and GLP-1 Therapy: Key Counseling Points for Pharmacists
4
Severe Asthma's Effects May Extend Beyond the Lungs, Brain Imaging Study Suggests
5